Gilead Persuades NICE To Overturn Zydelig Recommendation
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. has managed to persuade NICE, the HTA body for England and Wales, to reverse an earlier recommendation that Zydelig (idelalisib) not be offered free of charge under the UK's NHS (National Health Service) for certain patients with chronic lymphocytic leukemia (CLL). The latest decision brings NICE in line with the Scottish Medicines Consortium, which approved Zydelig for use under NHS Scotland earlier this year.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.